ArticleCureus2023
Peripheral Neuropathy Secondary to Ertapenem Administration for Treatment of Infectious Endocarditis.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ertapenem is a widely used broad-spectrum carbapenem antibiotic active against most species of gram-negative and gram-positive aerobes and anaerobes with specific targeting of the Amp C extended-spectrum beta-lactamases. It is advantageous for its once-daily dosing via IM or IV administration and minimal side effect profile for the treatment of community-acquired infections. We report an 80-year-old man presenting with reversible peripheral neuropathy following the administration and subsequent discontinuation of ertapenem for the treatment of acute infectious endocarditis. It is especially notable that our patient had less severe (i.e., stage 3) chronic kidney disease as opposed to current literature which only presents similar findings with more advanced kidney disease (stage 4-5). Upon cessation of ertapenem administration, our patient recovered to his baseline motor and sensory status over a period of four days. We believe there to be value in reporting this case, as well as value in reevaluating the current recommendations for ertapenem dosing in those with kidney compromise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.